India, March 31 -- India has emerged as an important innovation hub for vaccine R&D. In the past few years, India has witnessed multiple outbreaks of fatal viruses such as the Nipah virus and has made significant progress in developing home-grown vaccines. In March 2025, Pune-based Gennova Biopharmaceuticals received grants worth $13.38 million to develop self-amplifying mRNA (saRNA) from the Coalition for Epidemic Preparedness Innovations (CEPI). Gennova will play a crucial role in validating the potential of the saRNA platform for vaccine development against nipah virus. The vaccine manufacturer aims to set new benchmarks using its saRNA platform. Gennova will also collaborate with the Houston Methodist Research Institute (HMRI), and de...